Selective oestrogen receptor downregulator.
Howell
Anthony
A
CRC Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, UK. maria.parker@christie-tr.nwest.nhs.uk
D000077384:Anastrozole; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D015536:Down-Regulation; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D009570:Nitriles / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000378:metabolism*; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use
D009570:Nitriles; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D014230:Triazoles; D013629:Tamoxifen; D000077267:Fulvestrant; D000077384:Anastrozole; D004958:Estradiol